KNSA vs. BMRN
KNSA (Kiniksa Pharmaceuticals, Ltd.) and BMRN (BioMarin Pharmaceutical Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, KNSA returned 29.11%/yr vs -6.84%/yr for BMRN. At a 0.34 correlation, their price movements are largely independent.
Performance
KNSA vs. BMRN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 16.00% return, which is significantly higher than BMRN's -8.03% return.
KNSA
- 1D
- 1.98%
- 1M
- -16.96%
- YTD
- 16.00%
- 6M
- 17.89%
- 1Y
- 64.38%
- 3Y*
- 48.51%
- 5Y*
- 29.11%
- 10Y*
- —
BMRN
- 1D
- 2.51%
- 1M
- -1.44%
- YTD
- -8.03%
- 6M
- 0.64%
- 1Y
- -3.75%
- 3Y*
- -16.34%
- 5Y*
- -6.84%
- 10Y*
- -4.86%
KNSA vs. BMRN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 16.00% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 44.27% |
BMRN BioMarin Pharmaceutical Inc. | -8.03% | -9.58% | -31.83% | -6.83% | 17.14% | 0.75% | 3.71% | -0.70% | -3.55% |
Correlation
The correlation between KNSA and BMRN is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (All Time) Calculated using the full available price history since May 25, 2018 | 0.34 |
The correlation between KNSA and BMRN shifts across timeframes, from 0.25 (1 year) to 0.35 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
KNSA:
$3.94B
BMRN:
$10.80B
KNSA:
$0.92
BMRN:
$1.37
KNSA:
51.96
BMRN:
39.85
KNSA:
0.50
BMRN:
2.39
KNSA:
5.03
BMRN:
3.30
KNSA:
6.51
BMRN:
1.74
KNSA:
$754.05M
BMRN:
$3.24B
KNSA:
$294.06M
BMRN:
$2.46B
KNSA:
$101.06M
BMRN:
$439.56M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. BMRN — Risk / Return Rank
KNSA
BMRN
KNSA vs. BMRN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KNSA | BMRN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.59 | ||
| Sortino ratioReturn per unit of downside risk | +2.28 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.01 | +0.29 |
| Calmar ratioReturn relative to maximum drawdown | 3.06 | -0.17 | +3.23 |
| Martin ratioReturn relative to average drawdown | 11.39 | -0.35 | +11.74 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KNSA | BMRN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.48 | -0.11 | +1.59 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.55 | -0.21 | +0.76 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.14 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.19 | 0.11 | +0.08 |
Drawdowns
KNSA vs. BMRN - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, smaller than the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for KNSA and BMRN.
Loading charts...
Drawdown Indicators
| KNSA | BMRN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -90.58% | +7.52% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -22.49% | +1.37% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | -49.83% | +15.69% |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | -57.64% | +4.47% |
Max Drawdown (10Y)Largest decline over 10 years | — | -62.09% | — |
Current DrawdownCurrent decline from peak | -19.55% | -63.35% | +43.80% |
Average DrawdownAverage peak-to-trough decline | -40.26% | -45.51% | +5.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.67% | 10.84% | -5.17% |
Volatility
KNSA vs. BMRN - Volatility Comparison
The current volatility for Kiniksa Pharmaceuticals, Ltd. (KNSA) is 10.38%, while BioMarin Pharmaceutical Inc. (BMRN) has a volatility of 15.30%. This indicates that KNSA experiences smaller price fluctuations and is considered to be less risky than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | BMRN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.38% | 15.30% | -4.92% |
Volatility (6M)Calculated over the trailing 6-month period | 33.56% | 27.79% | +5.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 43.77% | 34.57% | +9.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 53.49% | 32.87% | +20.62% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.66% | 35.51% | +28.15% |
Dividends
KNSA vs. BMRN - Dividend Comparison
Neither KNSA nor BMRN has paid dividends to shareholders.
Financials
KNSA vs. BMRN - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. BMRN - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
BMRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 571.21M and revenue of 766.21M. Therefore, the gross margin over that period was 74.6%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
BMRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported an operating income of 129.64M and revenue of 766.21M, resulting in an operating margin of 16.9%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
BMRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a net income of 105.53M and revenue of 766.21M, resulting in a net margin of 13.8%.
Frequently Asked Questions
KNSA and BMRN have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMRN has higher volatility (15.30%) compared to KNSA (10.38%). In terms of maximum drawdown, KNSA dropped -83.06% vs BMRN's -90.58%.
KNSA currently has the higher Sharpe Ratio (1.48 vs -0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and BMRN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer